dc.creatorShah, Kiran
dc.creatorTiwaskar, Mangesh
dc.creatorChawla, Purvi
dc.creatorKale, Mayura
dc.creatorDeshmane, Rajesh
dc.creatorSowani, Alpana
dc.date.accessioned2020-08-21T16:03:24Z
dc.date.accessioned2022-09-23T18:56:41Z
dc.date.available2020-08-21T16:03:24Z
dc.date.available2022-09-23T18:56:41Z
dc.date.created2020-08-21T16:03:24Z
dc.identifierhttps://doi.org/10.1016/j.dsx.2020.07.003
dc.identifierhttp://hdl.handle.net/20.500.12010/12087
dc.identifierhttps://doi.org/10.1016/j.dsx.2020.07.003
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3510116
dc.description.abstractBackground: Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food, outpatient clinics, pathological services and medicines. Aim: To assess the factors associated with the risk of hypoglycemia during AprileMay 2020 lockdown in people with type 2 diabetes mellitus. Methodology: We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM) reporting to the emergency department (ED) during lockdown period with symptoms suggestive of hypoglycemia. Results: The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value (50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU (60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ) 400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%, and 32.88%) respectively. Conclusion: The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities. Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia
dc.languageeng
dc.publisherDiabetes & Metabolic Syndrome: Clinical Research & Reviews
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAcceso restringido
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectHypoglycemia
dc.subjectAnti-diabetic agents
dc.subjectCOVID-19
dc.subjectComorbidities
dc.titleHypoglycemia at the time of Covid-19 pandemic


Este ítem pertenece a la siguiente institución